Tumor cell migration/invasion pathways (null)

Tumor cell migration/invasion pathways encompass the molecular mechanisms that permit cancer cells to move from the primary tumor mass and invade adjacent tissues. This process usually begins with the epithelial-to-mesenchymal transition (EMT), where epithelial cancer cells lose their tight cell–cell junctions (often via reduced E-cadherin and increased N-cadherin) and acquire a more motile, invasive phenotype. Key elements include the activation of transcription factors (Snai1/2, Twist, Zeb1/2), stimulation by pathways such as TGF-β, NF-κB, Wnt, and Notch, and secretion of enzymes like matrix metalloproteinases (MMPs), which degrade extracellular matrix barriers[1][2][3][4]. Migrating cancer cells exhibit diverse forms—some move individually (mesenchymal or amoeboid), while others migrate collectively. These behaviors are highly regulated by environmental signals, matrix composition, and intracellular signaling cascades. The pathways are central to tumor metastasis and represent a major challenge in cancer therapy, contributing to treatment resistance and disease progression. In summary: "Tumor cell migration/invasion pathways" is a process category, not a discrete, targetable molecule, and thus should not be listed as a canonical drug target according to standard molecular classification frameworks[2][3][4].

Other names

Tumor cell migration pathwaysCancer invasion pathwaysMetastasis pathways

Inhibition of proteolytic enzymes (e.g., MMP inhibitors to block ECM degradation); Inhibition of signal transduction (e.g., blocking kinases with small molecule inhibitors); Modulation of adhesion molecules or EMT regulators.